Drug Profile


Alternative Names: Benzoporphyrin derivative monoacid ring A; BPD; BPD-MA; CL 315555; CL 315585; CL 318952; Everteporfine; Verteporfin for injection - Novartis; Visudine; Visudyne

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer Bausch Health Companies; Valeant Pharmaceuticals International
  • Class Antineoplastics; Eye disorder therapies; Porphyrins; Small molecules
  • Mechanism of Action Immunomodulators; Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Choroidal neovascularisation; Central serous chorioretinopathy; Age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration; Choroidal neovascularisation
  • No development reported Central serous chorioretinopathy
  • Discontinued Breast cancer; Coronary artery restenosis; Diabetic macular oedema; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 18 Jul 2018 Verteporfin licensed to Cheplapharm Arzneimittel worldwide, except for USA
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top